Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 37%
Hold 26%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences has demonstrated robust growth in its revenue streams, with TAVR sales increasing by 10.6% year-over-year, amounting to approximately $1.16 billion and surpassing consensus estimates. The company's TMTT segment experienced impressive growth of 48.3% year-over-year, reflecting strong adoption of its Pascal and Evoque products. Furthermore, management has expressed increased confidence in achieving its prior 2026 sales guidance of 8-10% year-over-year growth, which reinforces a positive outlook for the company's financial trajectory.

Bears say

Edwards Lifesciences has demonstrated a mixed financial performance, with adjusted operating margin falling short of consensus estimates due to elevated selling, general, and administrative expenses, ultimately leading to a notable earnings per share miss. While the company's transcatheter aortic valve replacement (TAVR) sales exceeded consensus expectations, surgical structural heart sales lagged behind, reflecting broader risks such as hospital staffing issues, competition, and potential delays in product development. The outlook is further complicated by market dynamics, including the potential for slower growth trajectories in key segments and challenges from emerging competitors, which could hinder the company's ability to maintain its position in the medical device market.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.